Enacts GS 58-3-295 to prohibit an insured's copayment under a health benefit plan that covers insulin from exceeding $30 for a month's supply, or a proportional copayment for another quantity, regardless of the amount or types of insulin needed. Applies to insurers and pharmacy benefits managers.
Amends GS 58-56A-3 to authorize a pharmacy or pharmacist to provide an individual for whom the pharmacy or pharmacist is filling a prescription drug information, regarding the amount an individual would pay for the drug without coverage under a health benefit plan.
Enacts GS 90-85.15C to require pharmacists to inform, or designate a supervised individual to inform, all individuals for whom the pharmacist is filling a prescription drug or device about the availability of a therapeutically equivalent brand name drug or device that is the lowest cost alternative to the prescription and the cost difference between the two.
Applies to contracts issued, renewed, or amended on or after October 1, 2022.
Appropriates $250,000 from the General Fund to the Department of Health and Human Services for 2022-23 to provide staffing and technology to collect and report data related to the act to the NCGA and Council of State. Effective July 1, 2022.
|View NCGA Bill Details||2021|
AN ACT TO LIMIT AN INSURED'S COPAYMENT FOR INSULIN, TO AUTHORIZE PHARMACISTS TO PROVIDE INFORMATION REGARDING THE AMOUNT AN INDIVIDUAL WOULD PAY FOR A PRESCRIPTION DRUG WITHOUT INSURANCE COVERAGE, AND TO REQUIRE PHARMACISTS TO INFORM INDIVIDUALS REGARDING LOWER COST PRESCRIPTIONS.Intro. by Mohammed, Woodard, Crawford.
Status: Filed (Senate action) (May 26 2022)
Bill S 847 (2021-2022)Summary date: May 26 2022 - View Summary